Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06337097 · ClinicalTrials.gov registry record · NA
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
A NA study of Immune Checkpoint Therapy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 980
- Enrollment target
- 1
- Study location
NCT06337097 is a NA study of Immune Checkpoint Therapy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 980 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06337097, a NA study of Immune Checkpoint Therapy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 980 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects.
Conditions Studied
Interventions
- OTHER Standard of care
- DIAGNOSTIC_TEST Troponin surveillance
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 980 participants |
| Start Date | 2024-02-02 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06337097
The ClinicalTrials.gov registry entry for NCT06337097 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 980 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immune Checkpoint Therapy appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.
NCT06337097 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06337097 about?
NCT06337097 is a clinical study titled "STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy". To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects.
What is the current status of trial NCT06337097?
This trial is currently recruiting. It is a NA study. The enrollment target is 980 participants. The study started on 2024-02-02. Estimated completion is 2028-12-31.
What conditions does trial NCT06337097 study?
This clinical trial studies the following conditions: Immune Checkpoint Therapy.
What interventions are being tested in trial NCT06337097?
The interventions under investigation include: Standard of care (OTHER), Troponin surveillance (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06337097?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06337097 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Checkpoint Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.